Processing
Archer™ VARIANTPlex™ AML Focus panel
Discover key AML answers with a targeted DNA panel
Identify key single nucleotide variants, internal tandem duplications, insertions, and deletions with targeted NGS of 11 core genes relevant for acute myeloid leukemia (AML) research.
Detect confidently with Archer VARIANTPlex NGS Panels for DNA.
Talk to a technical sales expert
Learn how the VARIANTPlex AML Focus panel can identify key genomic alterations for your research.
Request a consultationProduct details
Panel specifications
| Specifications | |
|---|---|
| Targeted genes | 11 |
| Genomic alterations | SNVs, Indels, ITDs |
| Input nucleic acid required* | ≥10 ng |
| Recommended number of reads | 800 K |
| Hands-on time | <3.5 hours |
| Total library prep time | 1.5 days |
| Platform compatibility | Illumina® |
| Reagent format | Lyophilized or liquid |
| Supported sample types | Blood, bone marrow, fresh frozen, FFPE, BMMC, PBMC |
*Input mass requirements vary depending on type and quality. Unless the tumor cellularity and sample quality are high, 50 ng of FFPE-derived nucleic acid should be considered the minimum recommendation. If input is not limiting, 200 ng is recommended.
Gene targets
ASXL1
CEBPA
DNMT3A
FLT3
IDH1
IDH2
JAK2
KIT
NPM1
RUNX1
TP53
Interested in adding a few genes to this panel?
Customize this NGS panel by adding any of our functionally-tested designs or create a new panel that fits your exact requirements with Assay Marketplace.
Benefits
- Detect confidently—A unique outlier detection algorithm leverages position-specific data to enable variant detection even at low allele frequencies, one of the many ways that Archer Analysis empowers you to detect confidently.
- Less QNS—Anchored Multiplex PCR (AMP™) chemistry is designed for compatibility with a wide range of sample types, including low-input and degraded samples such as FFPE tissue.
- Achieve efficiency—Streamlined workflows for your lab are enabled by choice of reaction-sized lyophilized reagents or high-throughput liquid reagents, while parallel workflows across all Archer panels provide efficient genomic characterization.
- Customize content—Use Assay Marketplace to modify any panel to fit your lab’s needs or start from scratch to keep up with the pace of discovery.
Ready to start?
Talk with our technical sales team. Learn how the VARIANTPlex AML Focus panel can identify key genomic alterations for your research.
Request a consultationResources
Frequently asked questions
Can I analyze DNA and RNA simultaneously for comprehensive genomic profiling of blood cancers with Archer panels?
Yes, DNA and RNA from a single sample can be analyzed with VARIANTPlex™ and FUSIONPlex™ panels to provide a genomic profile of the blood cancer. For comprehensive genomic profiling, pair FUSIONPlex Pan Heme and VARIANTPlex Myeloid panels to interrogate 226 genes for fusions, splicing, exon-skipping, SNVs, indels, CNVs, ITDs and expression levels. Additionally, IMMUNOVerse™ assays can provide T- and B-cell clonality, MRD, and somatic hypermutation information relevant for heme malignancies. IMMUNOVerse panels have parallel workflows with VARIANTPlex and FUSIONPlex assays, allowing for comprehensive, streamlined blood cancer profiling.
Is it possible to detect low allele frequency (<1% AF) variants with VARIANTPlex™ panels?
Yes, minimal residual disease (MRD) / low allele frequency (LAF) can be optimized with VARIANTPlex panels with increased input, using a normalized dataset, increasing the sequencing depth, and using low allelic frequency cycling conditions. For more details on this use, please contact support.
What is the difference between Anchored Multiplex PCR (AMP™) and traditional priming methods for DNA NGS analysis?
As opposed to traditional priming methods, AMP chemistry enables tiling primers across both strands of DNA, optimally covering targeted regions for amplification and characterization of challenging, yet relevant alterations such as internal tandem duplications. Additionally, AMP chemistry uses molecular barcode adapters that bind to DNA fragments before amplification, allowing for efficient amplification of targets even from degraded or fragmented nucleic acid input, such as DNA from FFPE tissue and ctDNA from plasma.
Related products
RUO23-2355_001